We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The largest drug merger of all time could be at risk of falling through after the U.S. Treasury Department late Monday issued a set of regulations that reduce the benefit of tax inversion deals. Read More
Pricing transparency is a key ingredient in bringing down prescription drug costs, according to a policy paper from the American College of Physicians. Read More
The FTC is suing Endo Pharmaceuticals and several other drugmakers over what it calls the illegal use of pay-for-delay settlements to block the market entry of generic forms of Opana ER and Lidoderm. Read More
Actavis received a setback in its quest to market a generic version of Lialda following a district court’s decision upholding Shire’s patent covering the ulcerative colitis drug. Read More